These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 26500138)

  • 1. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
    Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
    Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
    Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
    Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thrombopoietin receptor agonists for platelet disorders.
    Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
    Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietic agents.
    Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
    Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of thrombopoietic agents.
    Rhodes E; Stasi R
    Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
    Tiu RV; Sekeres MA
    Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the potential for thrombopoietic agents in acute leukemia?
    Kuter DJ
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin: too much or too little.
    Newland A
    Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    Waisbren J; Dinner S; Altman J; Frankfurt O; Helenowski I; Gao J; McMahon BJ; Stein BL
    Int J Hematol; 2017 Jan; 105(1):44-51. PubMed ID: 27558575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing thrombocytopenia associated with cancer chemotherapy.
    Kuter DJ
    Oncology (Williston Park); 2015 Apr; 29(4):282-94. PubMed ID: 25952492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the role of novel thrombopoietic agents in the management of acute leukemia?
    Kuter DJ
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):372-378. PubMed ID: 27890262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.